Identification

Name
Bacitracin
Accession Number
DB00626  (APRD00816)
Type
Small Molecule
Groups
Approved, Vet approved
Description

Bacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy. Its unique name derives from the fact that the bacillus producing it was first isolated in 1943 from a knee scrape from a girl named Margaret Tracy. As a toxic and difficult-to-use antibiotic, bacitracin doesn't work well orally. However, it is very effective topically.

Bacitracin is synthesised via the so-called nonribosomal peptide synthetases (NRPSs), which means that ribosomes are not involved in its synthesis.

Structure
Thumb
Synonyms
  • Bacitracin a2a
  • Bacitracin F, 1-(N-((2-(1-amino-2-methylbutyl)-4,5-dihydro-4-thiazolyl)carbonyl)-L-leucine)-
  • Bacitracina
External IDs
NSC-45737
Product Ingredients
IngredientUNIICASInChI Key
Bacitracin methylene disalicylateJGV6OJ52FT55852-84-1Not applicable
Bacitracin zinc89Y4M234ES1405-89-6Not applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Baciject 50,000 Units/vialPowder, for solution50000 unitIntramuscular; TopicalSterimax Inc2003-08-28Not applicableCanada
Bacitracin for InjectionPowder, for solution50000 unitIntramuscular; TopicalFresenius KabiNot applicableNot applicableCanada
Bacitracin USPPowder, for solution50000 unitIntramuscular; TopicalPfizer1951-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BACiiMInjection, powder, lyophilized, for solution50000 [USP'U]/1IntramuscularX Gen Pharmaceuticals, Inc.1997-05-09Not applicableUs
BacitracinOintment500 [USP'U]/1gOphthalmicAkorn2013-12-132014-02-25Us
BacitracinInjection, powder, for solution50000 [USP'U]/1IntramuscularXellia Pharmaceuticals USA LLC2018-10-01Not applicableUs
BacitracinInjection, powder, for solution5000 [USP'U]/1mLIntramuscularPharmacia & Upjohn Inc1948-07-29Not applicableUs
BacitracinOintment500 [iU]/1gOphthalmicPhysicians Total Care, Inc.1994-04-29Not applicableUs
BacitracinInjection, powder, for solution5000 [USP'U]/1mLIntramuscularAkorn2017-10-23Not applicableUs
BacitracinOintment500 [iU]/1gOphthalmicRemedy Repack2013-02-082014-02-08Us
BacitracinOintment500 [iU]/1gOphthalmicFera Pharmaceuticals2010-01-112013-06-14Us
BacitracinOintment500 [iU]/1gOphthalmicE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1971-11-092009-07-31Us
BacitracinInjection, powder, for solution5000 [USP'U]/1mLIntramuscularPharmacia and Upjohn Company LLC1948-07-29Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Advanced First Aid BacitracinOintment500 1/1gTopicalAdvanced First Aid, Inc.2016-10-18Not applicableUs
Aftate Bacitracin ZincOintment500 [iU]/1gTopicalSabel Med Llc2016-05-01Not applicableUs
AntibioticOintment500 [USP'U]/1gTopicalMeijer Distribution2015-04-15Not applicableUs
antibiotic Bacitracin ZincOintment500 [iU]/1gTopicalMc Kesson2006-05-11Not applicableUs
antibiotic Bacitracin ZincOintment500 [iU]/1gTopicalA-S Medication Solutions2006-05-11Not applicableUs
Baciguent First Aid OintmentOintment500 unitTopicalJohnson & Johnson Merck Consumer Pharmaceuticals Of Canada1997-12-192008-08-07Canada
Baciguent First Aid Ointment 500units/gmOintment500 unitTopicalUpjohn1995-12-312001-07-26Canada
Baciguent Ointment 500 UnitsOintment500 unitTopicalUpjohn1951-12-311996-09-10Canada
Baciguent Oph Ont 500unit/gmOintment500 unitOphthalmicUpjohn1975-12-311997-08-28Canada
BacitinOintment500 unitTopicalPendopharm Division Of De Pharmascience Inc1984-12-31Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
10 Person ANSIBacitracin zinc (400 [iU]/1g) + Acetaminophen (325 mg/1) + Acetylsalicylic acid (325 mg/1) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Ibuprofen (200 mg/1) + Lidocaine (0.5 1/100g) + Neomycin sulfate (5 mg/1g) + Polymyxin B Sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL)KitGenuine First Aid2010-04-24Not applicableUs
25 Person ANSIBacitracin zinc (400 [iU]/1g) + Acetaminophen (325 mg/1) + Acetylsalicylic acid (325 mg/1) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Ethanol (62 g/100g) + Ibuprofen (200 mg/1) + Isopropyl Alcohol (70 mL/100mL) + Lidocaine (0.5 g/100g) + Neomycin sulfate (5 mg/1g) + Polymyxin B Sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL)KitGenuine First Aid2010-04-25Not applicableUs
50 Person ANSIBacitracin zinc (400 [iU]/1g) + Acetaminophen (325 mg/1) + Acetylsalicylic acid (325 mg/1) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Ethanol (62 g/100g) + Ibuprofen (200 mg/1) + Isopropyl Alcohol (70 mL/100mL) + Lidocaine (0.5 g/100g) + Neomycin sulfate (5 mg/1g) + Polymyxin B Sulfate (5000 [iU]/1g) + Water (98.16 mL/100mL)KitGenuine First Aid2010-06-02Not applicableUs
7 Select First Aid Triple AntibioticBacitracin zinc (400 [iU]/1g) + Neomycin sulfate (3.5 mg/1g) + Polymyxin B Sulfate (5000 [iU]/1g)OintmentTopical7-ELEVEN, INC.2016-12-08Not applicableUs
ACME FIRST AID Contains 404 PIECESBacitracin zinc (400 [iU]/1g) + Acetylsalicylic acid (81 mg/1) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Isopropyl Alcohol (70 mL/100mL) + Lidocaine (0.5 g/100g) + Neomycin sulfate (5 mg/1g) + Polymyxin B Sulfate (5000 [iU]/1g) + Water (98.16 mL/100mL)KitAcme United Corporation2010-04-27Not applicableUs
Acme Home/Office/Auto KitBacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Isopropyl Alcohol (0.7 mL/1mL) + Lidocaine hydrochloride (0.5 g/100g) + Neomycin sulfate (3.5 mg/1g) + Polymyxin B Sulfate (5000 [iU]/1g)KitDukal Corporation2010-05-012018-12-31Us
ACME Small Cuts and BurnsBacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Lidocaine (0.5 g/100g) + Neomycin sulfate (5 mg/1g) + Polymyxin B Sulfate (5000 [iU]/1g)KitAcme United Corporation2010-04-30Not applicableUs
Adventure First Aid .5 TinBacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (1.3 mg/1mL) + Benzocaine (0.6 mg/100mL) + Ethanol (60 mL/100mL) + Isopropyl Alcohol (700 mg/1mL) + Neomycin sulfate (5 mg/1g) + Polymyxin B Sulfate (5000 [iU]/1g)KitOral; TopicalTender Corporation2015-10-01Not applicableUs
Adventure Medical Kits 1-2 Person First AidBacitracin zinc (400 [iU]/1g) + Acetaminophen (500 mg/1) + Acetylsalicylic acid (325 mg/1) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Diphenhydramine hydrochloride (25 mg/1) + Ethanol (60 mL/100mL) + Ibuprofen (200 mg/1) + Neomycin sulfate (5 mg/1g) + Polymyxin B Sulfate (5000 [iU]/1g)KitTopicalTender Corp Dba Adventure Medical Kits2010-08-26Not applicableUs
Adventure Medical Kits 1-2 Person National Ski Patrol First AidBacitracin zinc (400 [iU]/1g) + Acetaminophen (500 mg/1) + Acetylsalicylic acid (325 mg/1) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Ibuprofen (200 mg/1) + Neomycin sulfate (5 mg/1g) + Polymyxin B Sulfate (5000 [iU]/1g)KitTender Corp Dba Adventure Medical Kits2010-08-26Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
MaxitrilBacitracin zinc (500 [USP'U]/1g) + Erythromycin (0.31 g/0.31g)KitTopicalFusion Pharmaceuticals LLC2010-02-082010-09-01Us
MytropheneBacitracin zinc (500 [USP'U]/1g) + Erythromycin (0.31 g/0.31g)KitTopicalFusion Pharmaceuticals LLC2010-05-152012-08-31Us
International/Other Brands
Baciguent (Upjohn)
Categories
UNII
DDA3RRX0P7
CAS number
1405-87-4
Weight
Average: 1422.693
Monoisotopic: 1421.748941023
Chemical Formula
C66H103N17O16S
InChI Key
CLKOFPXJLQSYAH-ABRJDSQDSA-N
InChI
InChI=1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35-,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48-,52-,53-,54-/m0/s1
IUPAC Name
(4R)-4-[(2S)-2-{[(4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazol-4-yl]formamido}-4-methylpentanamido]-4-{[(1S,2S)-1-{[(3S,6R,9S,12R,15S,18R,21S)-18-(3-aminopropyl)-12-benzyl-15-[(2S)-butan-2-yl]-3-(carbamoylmethyl)-6-(carboxymethyl)-9-(1H-imidazol-4-ylmethyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptaazacyclopentacosan-21-yl]carbamoyl}-2-methylbutyl]carbamoyl}butanoic acid
SMILES
CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC

Pharmacology

Indication

For the treatment of infants with pneumonia and empyema caused by staphylococci shown to be susceptible to the drug. Also used in ointment form for topical treatment of a variety of localized skin and eye infections, as well as for the prevention of wound infections. Used against gram positive bacteria. Bacitracin is also used as an inhibitor of proteases and other enzymes. However, specific activity of bactracin's inhibition of protein disulfide isomerase has been called into question.

Associated Conditions
Pharmacodynamics

Bacitracin is a mixture of related cyclic polypeptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy. As a polypeptide, toxic, and difficult to use chemical, bacitracin doesn't work well orally, however is very effective topically. Bacitracin exerts pronounced antibacterial action in vitro against a variety of gram-positive and a few gram-negative organisms. However, among systemic diseases, only staphylococcal infections qualify for consideration of bacitracin therapy.

Mechanism of action

Bacitracin intereferes with the dephosphorylation of the 55-carbon, biphosphate lipid transport molecule C55-isoprenyl pyrophosphate (undecaprenyl pyrophosphate), which carries the building blocks of the peptidoglycan bacterial cell wall outside the inner membrane for construction. Bacitracin binds divalent transition metal ions (Mn(II), Co(II), Ni(II), Cu(II), and Zn(II)) which binds and oxidatively cleave DNA.

TargetActionsOrganism
AC55-isoprenyl pyrophosphate
antagonist
Gram positive and gram negative bacteria
AInsulin-degrading enzyme
inhibitor
Human
UAlpha-2-macroglobulin
inhibitor
Human
Absorption

Absorption of bacitracin following intramuscular injection is rapid and complete. Absorption from the gastrointestinal tract following oral administration is not appreciable. Absorption following topical application is negligible.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

The drug is excreted slowly by glomerular filtration.

Half life
Not Available
Clearance
Not Available
Toxicity

Oral, mouse: LD50 = >3750 mg/kg.

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Bacitracin is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Bacitracin is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Bacitracin is combined with 4-hydroxycoumarin.
AbacavirBacitracin may decrease the excretion rate of Abacavir which could result in a higher serum level.
AcarboseBacitracin may decrease the excretion rate of Acarbose which could result in a higher serum level.
AceclofenacBacitracin may decrease the excretion rate of Aceclofenac which could result in a higher serum level.
AcemetacinThe risk or severity of nephrotoxicity can be increased when Bacitracin is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Bacitracin is combined with Acenocoumarol.
AclidiniumBacitracin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
AcrivastineBacitracin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Food Interactions
Not Available

References

Synthesis Reference

Brigt Oystese, "Zinc bacitracin composition for use as a feed supplement and method for making the same." U.S. Patent US4096246, issued December, 1963.

US4096246
General References
  1. Tay WM, Epperson JD, da Silva GF, Ming LJ: 1H NMR, mechanism, and mononuclear oxidative activity of the antibiotic metallopeptide bacitracin: the role of D-Glu-4, interaction with pyrophosphate moiety, DNA binding and cleavage, and bioactivity. J Am Chem Soc. 2010 Apr 28;132(16):5652-61. doi: 10.1021/ja910504t. [PubMed:20359222]
  2. Karala AR, Ruddock LW: Bacitracin is not a specific inhibitor of protein disulfide isomerase. FEBS J. 2010 Jun;277(11):2454-62. doi: 10.1111/j.1742-4658.2010.07660.x. Epub 2010 Apr 30. [PubMed:20477872]
External Links
Human Metabolome Database
HMDB0014764
KEGG Drug
D00128
KEGG Compound
C15482
PubChem Compound
10909430
PubChem Substance
46504727
ChemSpider
9084687
ChEBI
35862
ChEMBL
CHEMBL1200558
Therapeutic Targets Database
DAP000710
PharmGKB
PA448531
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Bacitracin
ATC Codes
D06AX05 — BacitracinJ01XX10 — BacitracinR02AB04 — Bacitracin
AHFS Codes
  • 52:04.04 — Antibacterials
  • 84:04.04 — Antibiotics
  • 08:12.28.08 — Bacitracins
MSDS
Download (71.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1CompletedTreatmentPlasma Cell Myeloma1
1RecruitingHealth Services ResearchBreast Implant Infection / Breast Reconstruction1
1WithdrawnTreatmentMinor burns1
2CompletedDiagnosticDermatitis, Allergic Contact1
2CompletedPreventionSinus Disease1
2CompletedTreatmentNon-Melanoma Skin Cancer (NMSC)1
2, 3RecruitingPreventionEdema Face1
2, 3RecruitingTreatmentSepsis1
2, 3WithdrawnTreatmentMinor burns1
3CompletedPreventionArrythmias1
3CompletedTreatmentCommunity Acquired Infections / Infections, Gram-Positive Bacterial / Pneumonia, Pneumococcal1
3RecruitingPreventionChronic Systolic Heart Failure / Complete atrioventricular heart block / Sick Sinus Syndrome / Syncope1
3RecruitingTreatmentFractures, Open1
4Active Not RecruitingPreventionArrythmias1
4CompletedPreventionPostoperative Infections1
4CompletedTreatmentFunctional Dyspepsia / Helicobacter Pylori / Peptic Ulcers1
4CompletedTreatmentHelicobacter Pylori Treatment Failure1
4CompletedTreatmentIndigestion / Peptic Ulcers1
4CompletedTreatmentPyelonephritis1
4CompletedTreatmentVertebral Osteomyelitis1
4RecruitingOtherOral Mucositis1
4RecruitingPreventionAntibiotic Allergy / Antibiotic Side Effect / Eyelid Diseases / Eyelid; Wound / Infection, Postoperative Wound / Skin Cancer Face / Surgical Incision / Surgical Site Infections / Surgical Wound, Recent1
4RecruitingTreatmentAntibiotic Resistance, Bacterial / Methicillin-Resistant Staphylococcus Aureus (MRSA) / Recurrences / Staphylococcal Skin Infections1
4RecruitingTreatmentPartial Thickness Burn1
4TerminatedTreatmentDiabetes, Diabetes Mellitus Type 1 / Foot Ulcer, Diabetic / Type 2 Diabetes Mellitus1
4Unknown StatusDiagnosticDermatitis, Allergic Contact1
4Unknown StatusTreatmentNative Arteriovenous Fistula1
4WithdrawnPreventionComplications; Breast Prosthesis, Infection or Inflammation1
4WithdrawnTreatmentPartial Thickness Burn1
Not AvailableCompletedNot AvailableDiverticulitis1
Not AvailableCompletedNot AvailablePenicillin Allergy1
Not AvailableCompletedPreventionInfection NOS1
Not AvailableCompletedTreatmentDiverticulitis, Colonic1
Not AvailableRecruitingTreatmentCancer, Breast1
Not AvailableRecruitingTreatmentLiver Cirrhosis / Small Intestinal Bacterial Overgrowth1
Not AvailableWithdrawnNot AvailableCystic Fibrosis (CF)1
Not AvailableWithdrawnPreventionBlood Stream Infections / Skin Diseases, Infectious1
Not AvailableWithdrawnTreatmentChronic Rhinosinusitis / Sinusitis1
Not AvailableWithdrawnTreatmentMinor burns1

Pharmacoeconomics

Manufacturers
  • X gen pharmaceuticals inc
  • App pharmaceuticals llc
  • Pfizer laboratories div pfizer inc
  • Pharmacia and upjohn co
  • Sagent pharmaceuticals inc
  • Altana inc
  • Eli lilly and co
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Combe inc
  • Naska pharmacal co inc div rugby darby group cosmetics
  • Apothekernes laboratorium a/s
  • Paddock laboratories inc
Packagers
  • Amend
  • APP Pharmaceuticals
  • Ben Venue Laboratories Inc.
  • CVS Pharmacy
  • Dispensing Solutions
  • DSM Corp.
  • E. Fougera and Co.
  • Fera Pharmaceuticals
  • Ivax Pharmaceuticals
  • Mckesson Corp.
  • Pharmacia Inc.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Redpharm Drug
  • Toku E Company
  • X-Gen Pharmaceuticals
Dosage forms
FormRouteStrength
OintmentTopical500 1/1g
KitOral; Topical
Kit
KitTopical
OintmentOphthalmic500 unit
OintmentTopical500 unit
CreamTopical500 [iU]/1g
InjectionIntramuscular50000 [iU]/1
Injection, powder, for solutionIntramuscular5000 [USP'U]/1mL
Injection, powder, for solutionIntramuscular50000 [iU]/10mL
Injection, powder, for solutionIntramuscular50000 [USP'U]/1
Injection, powder, for solutionIntramuscular50000 [iU]/1
Injection, powder, lyophilized, for solutionIntramuscular50000 [USP'U]/1
OintmentOphthalmic500 [USP'U]/1g
OintmentOphthalmic500 [iU]/1g
OintmentTopical500 [iU]/1g
OintmentTopical500 [USP'U]/1g
OintmentTopical500 1/1
Powder, for solutionIntramuscular; Topical50000 unit
Ointment; swabTopical
CreamTopical500 [USP'U]/1g
PowderTopical
CreamTopical
OintmentTopical.51 g/100g
SwabTopical
LozengeOral
StickTopical
OintmentOphthalmic
GelTopical
CreamTopical500 unit
OintmentOphthalmic; Topical
OintmentTopical
OintmentTopical500 U/1g
LiquidTopical
OintmentTopical400 [USP'U]/1g
SprayTopical500 [USP'U]/1g
Prices
Unit descriptionCostUnit
Bacitracin 5mm unit powder126.0USD each
Baciim strl 50000 unit vial19.8USD vial
Bacitracin 50000 unit vial13.31USD vial
Bacitracin 500 unit/gm ointmnt9.69USD g
CVS Pharmacy bacitracin 500 unit/gm oin0.15USD g
Sm first aid bacitracin ointmn0.1USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)221-225 °CNot Available
water solubilityFreely solubleNot Available
logP-0.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0245 mg/mLALOGPS
logP-2.9ALOGPS
logP-6.8ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)3.19ChemAxon
pKa (Strongest Basic)9.63ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count20ChemAxon
Hydrogen Donor Count17ChemAxon
Polar Surface Area530.87 Å2ChemAxon
Rotatable Bond Count31ChemAxon
Refractivity363.14 m3·mol-1ChemAxon
Polarizability147.15 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7857
Blood Brain Barrier-0.9943
Caco-2 permeable-0.7639
P-glycoprotein substrateSubstrate0.7416
P-glycoprotein inhibitor INon-inhibitor0.898
P-glycoprotein inhibitor IINon-inhibitor0.9697
Renal organic cation transporterNon-inhibitor0.9073
CYP450 2C9 substrateNon-substrate0.7482
CYP450 2D6 substrateNon-substrate0.7884
CYP450 3A4 substrateNon-substrate0.5435
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9011
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9122
Ames testNon AMES toxic0.7225
CarcinogenicityNon-carcinogens0.9045
BiodegradationNot ready biodegradable0.9799
Rat acute toxicity2.8201 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9936
hERG inhibition (predictor II)Non-inhibitor0.6586
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.
Kingdom
Organic compounds
Super Class
Organic Polymers
Class
Polypeptides
Sub Class
Not Available
Direct Parent
Polypeptides
Alternative Parents
Cyclic peptides / Glutamic acid and derivatives / Leucine and derivatives / Isoleucine and derivatives / N-acyl-alpha amino acids and derivatives / Macrolactams / Alpha amino acid amides / Thiazolecarboxamides / Imidazolyl carboxylic acids and derivatives / Benzene and substituted derivatives
show 16 more
Substituents
Polypeptide / Cyclic alpha peptide / Glutamic acid or derivatives / Leucine or derivatives / Isoleucine or derivatives / Macrolactam / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / N-substituted-alpha-amino acid / Alpha-amino acid or derivatives
show 37 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
homodetic cyclic peptide, polypeptide (CHEBI:35862) / Non-ribosomal peptides (C15482)

Targets

Kind
Small molecule
Organism
Gram positive and gram negative bacteria
Pharmacological action
Yes
Actions
Antagonist
References
  1. Stone KJ, Strominger JL: Mechanism of action of bacitracin: complexation with metal ion and C 55 -isoprenyl pyrophosphate. Proc Natl Acad Sci U S A. 1971 Dec;68(12):3223-7. [PubMed:4332017]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Plays a role in the cellular breakdown of insulin, IAPP, glucagon, bradykinin, kallidin and other peptides, and thereby plays a role in intercellular peptide signaling. Degrades amyloid formed by A...
Gene Name
IDE
Uniprot ID
P14735
Uniprot Name
Insulin-degrading enzyme
Molecular Weight
117967.49 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Medina V, Kesner L, Stracher A: Purification of nonantibiotic insulinase inhibitors from bacitracin. Biochem Med Metab Biol. 1993 Apr;49(2):255-64. [PubMed:8484964]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Tumor necrosis factor binding
Specific Function
Is able to inhibit all four classes of proteinases by a unique 'trapping' mechanism. This protein has a peptide stretch, called the 'bait region' which contains specific cleavage sites for differen...
Gene Name
A2M
Uniprot ID
P01023
Uniprot Name
Alpha-2-macroglobulin
Molecular Weight
163289.945 Da
References
  1. Maxfield FR, Davies PJ, Klempner L, Willingham MC, Pastan I: Epidermal growth factor stimulation of DNA synthesis is potentiated by compounds that inhibit its clustering in coated pits. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5731-5. [PubMed:42903]
  2. Dickson RB, Willingham MC, Pastan I: Binding and internalization of 125I-alpha 2-macroglobulin by cultured fibroblasts. J Biol Chem. 1981 Apr 10;256(7):3454-9. [PubMed:6162847]
  3. Dickson RB, Willingham MC, Gallo M, Pastan I: Inhibition by bacitracin of high affinity binding of 125I-alpha 2M to plasma membranes. FEBS Lett. 1981 Apr 20;126(2):265-8. [PubMed:6165617]
  4. Hanover JA, Cheng S, Willingham MC, Pastan IH: alpha 2-Macroglobulin binding to cultured fibroblasts. Solubilization and partial purification of binding sites. J Biol Chem. 1983 Jan 10;258(1):370-7. [PubMed:6184373]
  5. Gliemann J, Larsen TR, Sottrup-Jensen L: Cell association and degradation of alpha 2-macroglobulin-trypsin complexes in hepatocytes and adipocytes. Biochim Biophys Acta. 1983 Mar 31;756(2):230-7. [PubMed:6187372]

Drug created on June 13, 2005 07:24 / Updated on November 14, 2018 12:44